糖尿病患者合并非酒精性脂肪性肝病中年龄与糖尿病病程对肝脏相关事件风险的影响
香港地区性回顾性队列纳入2000至2014年诊断的7028例非酒精性脂肪性肝病合并2型糖尿病患者,随访至少5年,肝脏相关事件随年龄呈阈值效应,随糖尿病病程线性增加但年发生率无差异;年龄≥50岁和肝硬化是与肝脏相关事件相关的最强危险因素。
要点
- 肝脏相关事件随年龄呈阈值效应,<40岁、40-50岁和≥50岁分别有1.1%、4.9%和94.0%的患者发生肝脏相关事件。
- 肝脏相关事件随糖尿病病程线性增加,诊断后前10年与后续年份的年发生率无显著差异(0.06% vs. 0.10%;p=0.136)。
- 基线年龄≥50岁(aHR 2.01)和肝硬化(aHR 3.12)是与肝脏相关事件相关的最强危险因素。
核心结论
- 年龄而非2型糖尿病病程可预测非酒精性脂肪性肝病合并2型糖尿病患者的肝脏相关事件。
- 对非酒精性脂肪性肝病合并2型糖尿病患者从50岁开始筛查晚期肝病是合理的。
研究设计与样本
- 香港地区性回顾性队列研究,纳入2000至2014年诊断的非酒精性脂肪性肝病合并2型糖尿病成年患者,随访至少5年,共7028例(平均年龄56.1±13.3岁;男性3363例[47.9%])。
主要发现
- 随访77308人年期间,肝脏相关事件随年龄呈阈值效应,<40岁、40-50岁和≥50岁分别有1.1%、4.9%和94.0%的患者发生肝脏相关事件。
- 肝硬化随年龄同样呈阈值效应,<40岁、40-50岁和≥50岁分别有3.1%、5.1%和91.8%的患者发生肝硬化。
- 肝脏相关事件随糖尿病病程线性增加,诊断后前10年与后续年份的年发生率无显著差异(0.06% vs. 0.10%;p=0.136)。
- 多变量分析中,基线年龄≥50岁(aHR 2.01)和肝硬化(aHR 3.12)是与肝脏相关事件相关的最强危险因素。
- 以天冬氨酸氨基转移酶与血小板比值指数或Fibrosis-4指数替代肝硬化得到相似结果。
关键数值与推荐
- 肝脏相关事件定义为肝细胞癌和肝硬化并发症的复合终点。
临床怎么用
- 对非酒精性脂肪性肝病合并2型糖尿病患者从50岁开始筛查晚期肝病是合理的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver-related event development to guide screening strategies. APPROACH AND RESULTS: We conducted a territory-wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow-up. The primary endpoint was liver-related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow-up of 77,308 person-years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver-related events at the age of <40, 40-50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40-50, and ≥50 years, respectively. In contrast, liver-related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver-related events. Substitution of cirrhosis with the aspartate aminotransferase-to-platelet ratio index or the Fibrosis-4 index yielded similar results. CONCLUSIONS: Age rather than duration of T2D predicts liver-related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age.
引用
- Zhang X, Wong GL, Yip TC, et al. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. Hepatology. 2022. PMID: 35334125. doi:10.1002/hep.32476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。